Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPERINO, Justine
ORCID: 0000-0003-0039-0734
IDREF: 254309690
dc.contributor.authorCORAND, Virginie
dc.contributor.authorLAURENT, Elise
dc.contributor.authorTHEOPHILE, Helene
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMIREMONT-SALAME, Marie Ghada
ORCID: 0000-0002-6468-8903
IDREF: 153165766
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.contributor.authorCOLAS, Jean-Laurent
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorCOUFFINHAL, Thierry
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
IDREF: 221043470
dc.date.accessioned2022-06-03T09:52:59Z
dc.date.available2022-06-03T09:52:59Z
dc.date.issued2022-05-27
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140146
dc.description.abstractEnMonoclonal antibodies acting on the calcitonin gene related peptide or its receptor (CGRP-mabs) are novel drugs for resistant migraine prophylaxis. As CGRP-mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We report a case of myocardial infarction associated with erenumab. A 57-year-old woman with a familial history of coronaropathy, was first treated with erenumab 70 mg for 6 months, then increased to 140 mg. Almost five months after, the patient presented chest pain, increased troponin and abnormal electrocardiogram. A myocardial infarction without coronarography abnormality was diagnosed through MRI. Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP-mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate exams to measure the burden of coronary atherosclerosis, if necessary.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subject.enAdverse event
dc.subject.enCalcitonin gene-related peptide
dc.subject.enCase report
dc.subject.enPharmacovigilance
dc.subject.enDrug safety
dc.subject.enMigraine disorder
dc.title.enMyocardial infarction associated with erenumab: a case report.
dc.title.alternativePharmacotherapyen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/phar.2706en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed35620946en_US
bordeaux.journalPHARMACOTHERAPYen_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-03696664
hal.version1
hal.date.transferred2022-06-16T08:19:39Z
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PHARMACOTHERAPY&rft.date=2022-05-27&rft.eissn=1875-9114&rft.issn=1875-9114&rft.au=PERINO,%20Justine&CORAND,%20Virginie&LAURENT,%20Elise&THEOPHILE,%20Helene&MIREMONT-SALAME,%20Marie%20Ghada&rft.genre=article


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée